Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
attIL12-T cell therapy in advanced/metastatic soft tissue and bone sarcoma
NCT05621668Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2023
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of TRQ-1201 in soft tissue sarcoma (STS) and bone sarcoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events at 1 year, Maximum Tolerated Dose at 1 year and 1 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
TRQ-1201
03
Conditions
soft tissue sarcoma (STS)bone sarcoma
Beyond the preview
Go deeper on NCT05621668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621668.